Context Therapeutics INC Schedule 13G passive stakes

Octagon Capital Advisors LP, along with affiliated entities and its principal beneficial owner Ting Jia, has reported beneficial ownership of 3.3% of Context Therapeutics Inc. common stock.

BlackRock, Inc. has reported a beneficial ownership of 6.7% in Context Therapeutics Inc. common stock as of June 30, 2026.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, has reported beneficial ownership of 2,238,496 shares, representing 2.44% of Context Therapeutics Inc.'s common stock as of March 31, 2026.

Blue Owl Capital Holdings LP has filed a Schedule 13G, reporting beneficial ownership of 5,089,015 shares, representing 5.54% of Context Therapeutics Inc.'s common stock as of March 31, 2026.

Octagon Capital Advisors LP, along with its affiliates, has disclosed beneficial ownership of 5,250,000 shares, representing 5.7% of Context Therapeutics Inc.'s common stock.

Avidity Partners Management LP and affiliated entities have amended their Schedule 13G filing, reporting beneficial ownership of 8,302,808 shares of Context Therapeutics Inc. common stock, representing 8.7% of the class.

Soleus Capital Master Fund and affiliated entities have reported a 7.6% beneficial ownership stake in Context Therapeutics Inc.

Soleus Capital Master Fund and its affiliates have reported a 5.2% beneficial ownership stake in Context Therapeutics Inc., totaling 4,776,398 shares.

Avidity Partners Management LP and related entities reported a 9.9% beneficial ownership stake in Context Therapeutics Inc. as of September 30, 2025.

Great Point Partners, LLC and its managing members reported a 5.22% beneficial ownership stake in Context Therapeutics Inc., totaling 4,683,711 common shares.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, reported a continued beneficial ownership of 5.22% in Context Therapeutics Inc. common stock.

Avidity Partners and related entities have filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in Context Therapeutics Inc. as of June 30, 2025.

An amended Schedule 13G filing reveals that Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, collectively hold a 5.22% beneficial ownership in Context Therapeutics Inc.

Deep Track Capital, LP, along with its affiliates, has disclosed a passive beneficial ownership of 8.27% in Context Therapeutics Inc., totaling 7,419,355 shares of common stock.

Franklin Resources, Inc. has filed an amended Schedule 13G indicating its beneficial ownership in CONTEXT THERAPEUTICS INC. has decreased to 4.5% of the common stock.

Blue Owl Capital Holdings LP has reported a passive beneficial ownership of 8.48% in Context Therapeutics Inc., holding 6,357,928 shares as of December 31, 2024.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, have jointly reported a beneficial ownership of 6.25% of Context Therapeutics Inc.'s common stock as of December 31, 2024.

Avidity Partners Management LP and affiliated entities have filed an amended Schedule 13G, reporting a continued passive beneficial ownership of up to 9.9% in Context Therapeutics Inc. as of December 31, 2024.

Opaleye Management Inc. has filed an amended Schedule 13G, indicating it no longer holds a beneficial ownership stake in Context Therapeutics Inc. as of December 31, 2024.

An amended Schedule 13G filing reveals the current beneficial ownership stakes of Martin Lehr, the Martin Lehr 2000 Trust, and Ellyn Lehr in Context Therapeutics Inc. as of December 31, 2024.

Franklin Resources, Inc. and its subsidiary Franklin Advisers, Inc. have disclosed a 5.3% beneficial ownership stake in CONTEXT THERAPEUTICS INC. as of December 31, 2024.

MPM BioImpact LLC has reported a 16.4% beneficial ownership stake in Context Therapeutics Inc. as of December 31, 2024, through a Schedule 13G filing.